TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 389825
Drug: Bacampicillin 800
Normalized name: bacampicillin 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin 800 mg t.i.d. for ten days
Study: 389825
Drug: Ampicillin 2
Normalized name: ampicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 2 g t.i.d. for ten days
Study: 31305347
Drug: Titanium curette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium curette treatment
Study: 31305347
Drug: Carbon fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon fiber reinforced plastic curette treatment
Study: 31305347
Drug: Ultrasonic scaling
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic scaling with carbon fiber tip treatment
Study: 18647614
Drug: Morphosemantic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphosemantic treatment
Study: 18647614
Drug: Morphophonological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphophonological treatment
Study: 12974569
Drug: Concurrent reproduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent reproduction
Study: 12974569
Drug: Both concurrent
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both concurrent and delayed conditions
Study: 1329698
Drug: High-dose cyclosporine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclosporine
Study: 1329698
Drug: Corticosteroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids and cyclosporine (combination therapy)
Study: 6149592
Drug: Dopamine agonist,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist, apomorphine (AP)
Study: 6149592
Drug: Dopamine receptor
Normalized name: Dopamine receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine receptor blockade
Study: 31075323
Drug: Mediterranean/low-carbohydrate diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean/low-carbohydrate diet (MED/LC + 28 g walnuts/day)
Study: 27045811
Drug: Daily boost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily boost of 0.5 Gy
Study: 27045811
Drug: Weekly boost
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly boost of 2 Gy
Study: 26090731
Drug: Standard radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radiation dose
Study: 26090731
Drug: 37% reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37% reduced radiation dose
Study: 9190510
Drug: Rehabilitation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation plus relaxation therapy (six weekly sessions of breathing and relaxation instruction)
Study: 8109770
Drug: Ketorolac infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac infusion (30 mg IM premedication + 2 mg/h continuous infusion)
Study: 8109770
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (NaCl 0.9% IM bolus + 2 mL/h saline infusion)
Study: 2470245
Drug: FUra +
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUra + LV* (high dose 200 mg/m2)
Study: 2470245
Drug: FUra +
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUra + LV* (low dose 20 mg/m2)
Study: 2470245
Drug: FUra (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUra (single agent)
Study: 2470245
Drug: FUra +
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUra + LV* (both doses)
Study: 30302936
Drug: AZL‐M/CLD 40/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL‐M/CLD 40/25 mg
Study: 30302936
Drug: AZL‐M/CLD 40/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL‐M/CLD 40/12.5 mg
Study: 30302936
Drug: AZL‐M 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL‐M 40 mg
Study: 24576271
Drug: Multidisciplinary group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary group-based rehabilitation program with monthly motivational consultation from 6 to 12 months
Study: 20923610
Drug: AS03(B) adjuvanted
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(B) adjuvanted split-virion H1N1 vaccine
Study: 20923610
Drug: Non-adjuvanted whole-virion
Normalized name: HYACINTHOIDES NON-SCRIPTA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted whole-virion H1N1 vaccine
Study: 8245328
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (recombinant tissue-type plasminogen activator, urokinase, or a combination)
Study: 3802956
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant interferon-alpha-2a (1.5 X 10(6) U daily for one week)
Study: 3802956
Drug: High-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose recombinant interferon-alpha-2a (18 X 10(6) U daily for one week)
Study: 3802956
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group switched to high-dose (18 X 10(6) U daily for another 7 days)
Study: 3802956
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group switched to low-dose (3 X 10(6) U daily for another 7 days)
Study: 31870450
Drug: Patchouli alcohol
Normalized name: oil of patchouli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patchouli alcohol (PA) administered intranasally
Study: 23187648
Drug: Losartan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan treatment in patients with HFrEF
Study: 10523477
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 30 mg/day
Study: 10523477
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 60 mg/day
Study: 10523477
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 90 mg/day
Study: 10523477
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS mean dose of 52.3 mg/day during one-year open label phase
Study: 8748432
Drug: CI-988 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-988 (300 mg/day, thrice daily)
Study: 3885441
Drug: Oral analgesia
Normalized name: P-A-C Analgesic Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral analgesia with paracetamol 320 mg, caffeine 32 mg, codeine phosphate 8 mg, and meprobamate 150 mg (Stopayne)
Study: 3885441
Drug: Oral analgesia
Normalized name: P-A-C Analgesic Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral analgesia with dipyrone 500 mg, pitofenone hydrochloride 5 mg, and fenpiverinium bromide 0.1 mg (Baralgan HS)
Study: 3885441
Drug: Parenteral administration
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral administration of pethidine 100 mg
Study: 3885441
Drug: Parenteral administration
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral administration of dipyrone 2500 mg
Study: 31887803
Drug: Hyaluronidase injection
Normalized name: hyaluronidase Injection
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyaluronidase injection (5000 IU)
Study: 27591953
Drug: Low-dose vaccine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vaccine (7.5 mcg HA)
Study: 27591953
Drug: High-dose vaccine
Normalized name: Fluzone 2023-2024 high-dose vaccine Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vaccine (15 mcg HA)
Study: 24289244
Drug: 1064-nm Q-switched
Normalized name: Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1064-nm Q-switched Nd:YAG laser plus chemical peeling with Jessner's solution
Study: 16096831
Drug: Darifenacin 15
Normalized name: darifenacin 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin 15 mg once daily (q.d.)
Study: 16096831
Drug: Darifenacin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin 30 mg once daily (q.d.)
Study: 16096831
Drug: Oxybutynin 5
Normalized name: oxyBUTYnin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 5 mg three times daily (t.i.d.)
Study: 10603716
Drug: Immunohistochemical detection
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunohistochemical detection using LAM antibody
Study: 10603716
Drug: Immunohistochemical detection
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunohistochemical detection using PGL-1, 30 kD and 65 kD antibodies
Study: 2041036
Drug: felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: felodipine 5 mg ER formulation
Study: 6992910
Drug: Naftidrofuryl (Praxilene)
Normalized name: naftidrofuryl
DrugBank: Naftidrofuryl (DB13588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (Praxilene) 200 mg t.d.s. for 6 months
Study: 26107684
Drug: Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium Carbonate Chewable D3 tablet (thrice daily)
Study: 26107684
Drug: MESE exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: MESE exercise (thrice daily, 7 repetitions per time for 12 months)
Study: 26107684
Drug: MESE exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: MESE exercise + Calcium Carbonate Chewable D3 tablet (thrice daily for 12 months)
Study: 26107684
Drug: MESE exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: MESE exercise + Calcium Carbonate Chewable D3 tablet
Study: 21040197
Drug: LFD fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LFD fluconazole prophylaxis (twice a week for up to 6 weeks)
Study: 17466699
Drug: Cefazolin administered
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin administered 15-60 minutes prior to skin incision
Study: 17466699
Drug: Cefazolin administered
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin administered at the time of cord clamping
Study: 15478524
Drug: Midodrine 5
Normalized name: midodrine 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine 5 mg
Study: 10021952
Drug: Epidural F
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural F (fentanyl bolus 2 micrograms.kg‐1 in 0.5 ml.kg‐1 saline followed by 2 micrograms.ml‐1 fentanyl infusion)
Study: 10021952
Drug: Epidural F‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural F‐B (fentanyl bolus 2 micrograms.kg‐1 in 0.5 ml.kg‐1 bupivacaine 0.25% followed by 2 micrograms.ml‐1 fentanyl infusion in bupivacaine 0.125%)
Study: 25430779
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg GSK561679 (low-GSK)
Study: 25430779
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg GSK561679 (high-GSK)
Study: 20089518
Drug: Functional MBL
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional MBL deficiency (serum MBL levels of or below 100 ng/mL)
Study: 20089518
Drug: MBL levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBL levels >100 ng/mL
Study: 14639800
Drug: DHA-enriched eggs
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-enriched eggs (147 mg DHA/egg)
Study: 14639800
Drug: Ordinary eggs
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary eggs (20 mg DHA/egg)
Study: 14639800
Drug: DHA-enriched eggs
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-enriched eggs (147 mg DHA/egg) in subjects with BMI >= 30 kg/m2
Study: 14639800
Drug: Ordinary eggs
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary eggs (20 mg DHA/egg) in subjects with BMI >= 30 kg/m2
Study: 10868315
Drug: Ropinirole (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole (0.5 mg bid, titrated to a maximum of 6.0 mg tid)
Study: 10868315
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of L-dopa and ropinirole
Study: 8989068
Drug: Sparfloxacin (Spfx),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin (Spfx), 400 mg on day 1, then 200 mg once daily for 10 to 14 days
Study: 8989068
Drug: Roxithromycin (ROXI),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (ROXI), 150 mg twice daily for 10 to 14 days
Study: 1456812
Drug: Aclarubicin in
Normalized name: aclarubicin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclarubicin in combination with cytarabine (7 + 7)
Study: 1456812
Drug: Aclarubicin in
Normalized name: aclarubicin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclarubicin in combination with cytarabine (5 + 5)
Study: 1456812
Drug: Aclarubicin in
Normalized name: aclarubicin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclarubicin in combination with cytarabine (7 & 3)
Study: 1456812
Drug: Aclarubicin in
Normalized name: aclarubicin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclarubicin in combination with cytarabine (7 + 3)
Study: 31698825
Drug: Pemafibrate 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemafibrate 0.4 mg/day
Study: 31698825
Drug: Pemafibrate (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemafibrate (all doses)
Study: 29379953
Drug: Extended intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended intervention (medication review, 3 motivational interviews, follow-up with primary care physician, pharmacy, and nursing home)
Study: 29379953
Drug: Basic intervention
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic intervention (medication review)
Study: 22328287
Drug: HAIC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAIC plus systemic chemotherapy (combined therapy)
Study: 22328287
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy alone (monotherapy)
Study: 20123413
Drug: Buccal-plus-lingual infiltrations
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal-plus-lingual infiltrations
Study: 10707439
Drug: Fluoxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (10 mg daily for 16 days, then 20 mg for 10 days, continuing for at least 3 months) + Nicotine inhalers (6-12 units/day for up to 6 months)
Study: 10707439
Drug: Nicotine inhalers
Normalized name: nicotine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine inhalers (6-12 units/day for up to 6 months) + Placebo (10 mg daily for 16 days, then 20 mg for 10 days, continuing for at least 3 months)
Study: 1763608
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium followed by daily oral magnesium tablets
Study: 1763608
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion followed by daily oral placebo tablets
Study: 29304744
Drug: High carotenoid
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carotenoid diet (375 g/d high carotenoid vegetables, 300 g/d high carotenoid fruit, 40-60 ml extra-virgin olive oil)
Study: 29304744
Drug: Lower carotenoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower carotenoid diet (375 g/d lower carotenoid vegetables, 300 g/d lower carotenoid fruit, 40-60 ml PUFA based oil)
Study: 27135207
Drug: Adjunctive couples
Normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive couples intervention (n=19)
Study: 17986161
Drug: Tramadol added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol added to transdermal fentanyl (group T)
Study: 17986161
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl alone (group F)
Study: 24878686
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted smoking cessation intervention (8 weekly 40-min counseling sessions with Korean-specific cultural elements)
Study: 24878686
Drug: Standard smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard smoking cessation intervention (8 weekly 10-min counseling sessions not culturally adapted)
Study: 23134470
Drug: Daily everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily everolimus (7.5 mg)
Study: 23134470
Drug: Weekly everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly everolimus (70 mg)
Study: 23134470
Drug: Daily everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily everolimus (7.5 mg) in HBsAg‐seropositive patients
Study: 23134470
Drug: Weekly everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly everolimus (70 mg) in HBsAg‐seropositive patients
Study: 15199081
Drug: Oxymorphone ER
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone ER 20 mg q12h for 1 day
Study: 12815774
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (7.5% - 1 ml/kg b.w.)
Study: 11593959
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral treatment
Study: 2952435
Drug: Random blood
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random blood glucose measurement (thresholds: 6.1 mmol/l within 2 h of eating, 5.6 mmol/l at greater than 2 h of food)
Study: 2952435
Drug: Formal oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formal oral glucose tolerance test
Study: 28767209
Drug: Suvorexant (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant (15 mg/d)
Study: 9268234
Drug: Simvastatin 5
Normalized name: simvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 5 mg/day
Study: 8337639
Drug: Local anaesthesia
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthesia with intravenous sedation
Study: 26490353
Drug: Fostamatinib 50-200
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostamatinib 50-200 mg (single and multiple dosing)
Study: 26490353
Drug: Fostamatinib 150
Normalized name: fostamatinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib 150 mg (single dose)
Study: 26490353
Drug: Fostamatinib 100
Normalized name: fostamatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib 100 and 200 mg (open-label study)
Study: 26490353
Drug: Fostamatinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib (all doses)
Study: 26490353
Drug: Fostamatinib 200
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostamatinib 200 mg
Study: 11446908
Drug: Amoxicillin-sulbactam 875/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-sulbactam 875/125 mg
Study: 11446908
Drug: Sulbactam 125
Normalized name: sulbactam 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulbactam 125 mg
Study: 9506730
Drug: G+T (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: G+T (three large gin with regular tonics, 0.5 g/kg alcohol and 60 g carbohydrate)
Study: 9506730
Drug: G alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: G alone (same amount of alcohol with Slim‐line tonic, 0.5 g carbohydrate)
Study: 9506730
Drug: G+T
Normalized name: Gentamicin + Tobramycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: G+T
Study: 7890893
Drug: alpha‐2a interferon,
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐2a interferon, 1 megaunit thrice weekly for 6 months
Study: 7890893
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no maintenance treatment)
Study: 3126012
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (NTG) 10 mg/24 h
Study: 27337519
Drug: Tribulus terrestris
Normalized name: TRIBULUS TERRESTRIS
DrugBank: Tribulus terrestris (DB14358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribulus terrestris (750 mg in three divided doses for three months)
Study: 25977745
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 0.5 mg three times a day
Study: 25977745
Drug: Methylprednisolone (mPSL)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (mPSL) 1 mg/kg three times a day
Study: 21972156
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg of nitroglycerin plus 2.5 mg of verapamil (Group 1)
Study: 21972156
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of verapamil alone (Group 2)
Study: 18775652
Drug: Cortisol and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol and dexamethasone treatment under basal conditions in responders